Fred Aslan - 06 Oct 2026 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ARTV
Reported as of: 06 Oct 2026
Net transaction value: -$168,880
SEC form: 4
Accepted by SEC: 07 Oct 2026, 16:02:00 UTC
Prior SEC filing: 06 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Bush, Attorney-in-Fact

Filing notes and source

Key filing fact

Fred Aslan filed Form 4 for Artiva Biotherapeutics, Inc. (ARTV) on 07 Oct 2026.

Key facts

This page summarizes Fred Aslan's Form 4 filing for Artiva Biotherapeutics, Inc. (ARTV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Oct 2026, 16:02.

Change

Previous filing in this sequence was filed on 06 Oct 2026.
Current net transaction value: -$168,880.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001909362 Primary reporting owner

Aslan Fred

Relationship: Chief Executive Officer, Director
Address: C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO
Signature: /s/ Jennifer Bush, Attorney-in-Fact
Signature date: 07 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARTV transaction

Common Stock

Sale

Transaction value: -$168,880
Shares: -23,463
Change %: -1.5%
Price: $7.20
Shares after: 1,519,606
Date: 06 Oct 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026.

Footnote F2

The weighted average sale price for the transaction reported was $7.1977, and the range of prices were between $6.92 and $7.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.